These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22456294)

  • 41. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial.
    Pan C; Yang W; Barona JP; Wang Y; Niggli M; Mohideen P; Wang Y; Foley JE
    Diabet Med; 2008 Apr; 25(4):435-41. PubMed ID: 18341596
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Update: vildagliptin for the treatment of Type 2 diabetes.
    Garber AJ; Sharma MD
    Expert Opin Investig Drugs; 2008 Jan; 17(1):105-13. PubMed ID: 18095923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dipeptidyl peptidase-4 inhibition by vildagliptin and the effect on insulin secretion and action in response to meal ingestion in type 2 diabetes.
    Dalla Man C; Bock G; Giesler PD; Serra DB; Ligueros Saylan M; Foley JE; Camilleri M; Toffolo G; Cobelli C; Rizza RA; Vella A
    Diabetes Care; 2009 Jan; 32(1):14-8. PubMed ID: 18931099
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study.
    Saab C; Al-Saber FA; Haddad J; Jallo MK; Steitieh H; Bader G; Ibrahim M
    Vasc Health Risk Manag; 2015; 11():149-55. PubMed ID: 25750538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
    Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
    Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
    Prasanna Kumar KM; Phadke U; Brath H; Gawai A; Paldánius PM; Mathieu C
    Prim Care Diabetes; 2016 Dec; 10(6):452-458. PubMed ID: 27353459
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus.
    Forst T; Dworak M; Berndt-Zipfel C; Löffler A; Klamp I; Mitry M; Pfützner A
    Diabetes Obes Metab; 2013 Jun; 15(6):576-9. PubMed ID: 23384119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.
    Bunck MC; Poelma M; Eekhoff EM; Schweizer A; Heine RJ; Nijpels G; Foley JE; Diamant M
    J Diabetes; 2012 Jun; 4(2):181-5. PubMed ID: 22051153
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
    González-Ortiz M; Sánchez-Peña MJ; González-Ortiz LJ; Robles-Cervantes JA; García-Ortega YE; Gómez-Gaitán EA; Pérez-Rubio KG; Martínez-Abundis E
    Diabetes Technol Ther; 2013 Jul; 15(7):564-8. PubMed ID: 23617250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
    Matikainen N; Mänttäri S; Schweizer A; Ulvestad A; Mills D; Dunning BE; Foley JE; Taskinen MR
    Diabetologia; 2006 Sep; 49(9):2049-57. PubMed ID: 16816950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vildagliptin: a review of its use in type 2 diabetes mellitus.
    Keating GM
    Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
    Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
    Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
    Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
    Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
    Blüher M; Schweizer A; Bader G; Foley JE
    Vasc Health Risk Manag; 2014; 10():661-4. PubMed ID: 25429228
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus.
    Croxtall JD; Keam SJ
    Drugs; 2008; 68(16):2387-409. PubMed ID: 18973400
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term efficacy and safety of vildagliptin add-on therapy in type 2 diabetes mellitus with insulin treatment.
    Kanazawa I; Tanaka KI; Notsu M; Tanaka S; Kiyohara N; Koike S; Yamane Y; Tada Y; Sasaki M; Yamauchi M; Sugimoto T
    Diabetes Res Clin Pract; 2017 Jan; 123():9-17. PubMed ID: 27914297
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
    Balas B; Baig MR; Watson C; Dunning BE; Ligueros-Saylan M; Wang Y; He YL; Darland C; Holst JJ; Deacon CF; Cusi K; Mari A; Foley JE; DeFronzo RA
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1249-55. PubMed ID: 17244786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.